2024 Archive

Read and Download 2024 Reports

Learn about new approvals and the state of the field for each quarter of 2024.

Q1 2024

The field earned the approval of three new therapies—a CAR-T therapy for myeloma in China, an AAV gene therapy for hemophilia B in Canada, and an autologous cell therapy for melanoma in the United States.

Q2 2024

In Q2, two new RNA therapies were approved in the US; Rytelo was approved for myelodysplastic syndrome and mRESVIA, an mRNA vaccine, was approved for respiratory syncytial virus (RSV) prophylaxis.

Q3 2024

While we saw only one new approval (Tecelra for synovial sarcoma), there are dynamic shifts deeper in the pipeline. The field is steadily diversifying; 51% of newly initiated gene therapy trials are now for non-oncology indications, up from just 39% year-over-year.

Q4 2024

We saw approvals across three modalities in Q4: Aucatzyl for acute lymphocytic leukemia, RegeneCyte for blood disorders, and Tryngolza for lipoprotein lipase deficiency

2025

28th ASGCT Annual Meeting

May 13-17, 2025 | New Orleans

This site uses cookies to offer you a better user experience and to analyze site traffic. By continuing to use this website, you accept our use of cookies.